VNRX VolitionRX Limited

-0.02 (-2.67%)
Last Updated: 13:09:59
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 100,578
Bid Price
Ask Price
News -
Day High 0.760051


52 Week Range


Day Low 0.7201
Company Name Stock Ticker Symbol Market Type
VolitionRX Limited VNRX AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -2.67% 0.73 13:09:59
Open Price Low Price High Price Close Price Prev Close
0.741 0.7201 0.760051 0.75
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
182 100,578 $ 0.7429338 $ 74,723 - 0.6265 - 2.7399
Last Trade Time Type Quantity Stock Price Currency
13:11:01 14 $ 0.72 USD

VolitionRX Limited Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
57.04M 78.14M - 306k -30.27M -0.39 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

VolitionRX News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No VNRX Message Board. Create One! See More Posts on VNRX Message Board See More Message Board Posts

Historical VNRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.071.0950.62650.7318551538,380-0.34-31.78%
1 Month1.241.380.62650.9089339220,770-0.51-41.13%
3 Months1.411.550.62651.14169,059-0.68-48.23%
6 Months1.652.100.62651.39144,843-0.92-55.76%
1 Year1.502.73990.62651.71143,943-0.77-51.33%
3 Years3.136.670.62653.04161,393-2.40-76.68%
5 Years2.447.690.62653.37176,449-1.71-70.08%

VolitionRX Description

VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.